In Phase C, participants will receive ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Members will obtain treatment till condition progression or even the individuals are not able to tolerate the study drugs. and afterwards endorse H3K27Ac at this location. Chromatin hyperacetylation could improve the https://clinicaleffectivenessofab67912.blogpayz.com/32108221/facts-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-revealed